Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
528actual
Sites
45
Countries
Austria, Canada, France +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-12-18 | actual | When the study began enrolling |
| Primary completion | 2024-09-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-11 | estimated | The whole study's end, after follow-up |
| First posted | 2017-11-07 | actual | When this record first appeared on the registry |
| Results posted | 2025-10-27 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-10-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Durvalumab
- Drug: Danvatirsen — also filed as AZD9150
- Drug: Ceralasertib — also filed as AZD6738
- Drug: Vistusertib
- Drug: Olaparib
- Drug: Oleclumab
- Drug: Trastuzumab deruxtecan — also filed as T-DXd
- Drug: Cediranib — also filed as AZD2171
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)
measured Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-10-09 · 12.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-02-15 · 21.7 MB · SAP_001.pdf
Publications
- PMID 38351187 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed